Stay updated with breaking news from Growth Differentiation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 2, 2024, at 11:30 AM CDT CatalYm today announced that positive new follow-up results from its ongoing "GDFATHER"
Oral presentation highlights first data from the GDFATHER-2a trial demonstrating lasting and confirmed responses (as per RECIST criteria) following treatment with visugromab and the anti-PD-1 inhibitor
Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 4 at 9:45 AM CDT CatalYm today announced that the first results from its ongoing Phase 2a trial "GDFATHER-2"
FinancialContent fully hosted finance channel
FogPharma is preclinical, but not for long. The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs.